| 组蛋白去乙酰化酶抑制剂与肾脏疾病 |
| |
| 引用本文： | 杜晓艳,冯宇颖,马良,付平. 组蛋白去乙酰化酶抑制剂与肾脏疾病[J]. 中华肾病研究电子杂志, 2019, 8(5): 226-229. DOI: 10.3877/cma.j.issn.2095-3216.2019.05.007 |
| |
| 作者姓名： | 杜晓艳 冯宇颖 马良 付平 |
| |
| 作者单位： | 1. 610041 四川大学华西医院 临床药学部/药剂科2. 四川大学华西医院 肾内科 |
| |
| 基金项目： | 国家自然科学基金项目资助(81570668) |
| |
| 摘 要： | 组蛋白去乙酰化是组蛋白表观遗传学修饰的重要的方式之一。组蛋白去乙酰化酶(HDACs)作为调控基因的关键蛋白，其功能异常早已被证实与肿瘤、神经退行性病变、肾脏病等发生和发展关系密切，进而推动HDAC抑制剂(HDACi)的研发及临床应用。本文综述HDACs在肾脏病发生发展中的作用及HDACi在肾脏病治疗中的应用前景。
|
| 关 键 词： | 表观遗传学 组蛋白 组蛋白去乙酰化酶抑制剂 肾脏病 |
| 收稿时间： | 2019-03-28 |
Histone deacetylase inhibitors and kidney diseases |
| |
| Xiaoyan Du,Yuying Feng,Liang Ma,Ping Fu. Histone deacetylase inhibitors and kidney diseases[J]. Chinese Journal of kidney disease investigation (Electronic Edition), 2019, 8(5): 226-229. DOI: 10.3877/cma.j.issn.2095-3216.2019.05.007 |
| |
| Authors: | Xiaoyan Du Yuying Feng Liang Ma Ping Fu |
| |
| Affiliation: | 1. Department of Pharmacy; West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China2. Department of Nephrology; West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China |
| |
| Abstract: | Histone deacetylation is one of the important ways of epigenetic modification of histones. Histone deacetylases (HDACs), as key proteins in regulating genes, has long been confirmed to be closely related to the occurrence and development of tumors, neurodegenerative diseases, and kidney diseases, promoting the development and clinical application of HDAC inhibitors (HDACi). This article reviewed the role of HDACs in the development and progression of kidney diseases, as well as the application prospect of HDACi in the treatment of kidney diseases. |
| |
| Keywords: | Epigenetics Histone Histone deacetylase inhibitor Kidney disease |
|
| 点击此处可从《中华肾病研究电子杂志》浏览原始摘要信息 |
|
点击此处可从《中华肾病研究电子杂志》下载全文 |
